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Abstract: This study reviews the literature and the practice of ac-
counting for research and development (R&D) costs from the first 
reference in 1917 to the current treatment. The conceptual treatment 
of R&D is compared to current financial accounting rules and expla-
nation of the evolution of the current rules is presented. The eco-
nomic and social consequences of the current rules which require 
R&D costs to be expressed are examined. The paper explores possible 
alternative treatment of R&D costs. As a contrast to U.S. practice, the 
accounting treatment of R&D costs in other countries is discussed. 
Given the findings of this paper, a strong case can be made for 
changing the way that R&D costs are accounted for in the United 
States. 
In today's rapidly changing world which relies increasingly 
on technology, the investments made in research and develop-
ment (R&D ) are more critical than ever to the economic future 
of companies and countries. The current financial accounting 
for R & D costs in the United States is to expense these costs as 
incurred.1 While this accounting treatment is certainly question-
1 Attempts have been made by authors such as Higgins (1954) to distinguish 
between research costs and development costs: 
Development costs are usually thought of as being the costs of 
attempting to convert the results of research to a commercial basis. 
Since the terms "research" and "development" are often used inter-
changeably, it is important to distinguish between the two. Re-
search in industry today is usually used in connection with prod-
ucts currently being produced or with new products and is com-
monly termed "general research." It includes the study of the suit-
ability of materials for specific purposes, the experimental testing 
of material, the study of manufacturing processes, and techniques 
and similar research work. 
Unless otherwise indicated, which is frequently done, R&D costs are consid-
ered as a single cost in this paper. Development costs are frequently referred to 
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able from a theory standpoint, the expense-as-incurred rule may 
have a practical consequence of being a disincentive to firms 
making R&D expenditures. Arguably, as a consequence, the cur-
rent accounting treatment may hinder the United States' eco-
nomic position in the global marketplace. 
In this paper, the history of accounting for research and 
development costs is analyzed to determine why the current 
accounting rules require immediate expensing. Thus, the evolu-
tion of accounting rules is traced from 1917 to the present. The 
reporting environment, issues and investigation conducted by 
the FASB in 1974 which led to the expense-as-incurred rule is 
examined. Particularly significant to the thesis of this paper is 
empirical evidence that was available at the time to counter the 
FASB's overly pessimistic assessment of the likely outcome of 
an R&D expenditure. The paper then reviews the more recent 
pronouncement about accounting for software development 
costs as a contrast to R&D accounting. Finally the paper exam-
ines how other countries account for R&D costs as another con-
trast to the U.S. practice, despite the similarity to the U.S. ac-
counting problem. Before tracing the historical evolution of the 
accounting for research and development costs, the paper exam-
ines the importance of R&D and the importance of how R&D 
costs are accounted for in the next section of the paper. 
OVERVIEW OF THE R&D ISSUE 
Clearly, R&D costs are necessary for the survival of many 
businesses and are the "engine that drives our economy." Solow 
[1957] estimated that 90 percent of the per capita increase in 
output between 1909 and 1949 was caused by technological 
change. Furthermore, the Committee for Economic Develop-
ment [Denison, 1962] estimated 36 percent of the increase in 
output per worker between 1929 and 1957 was caused by re-
search and development, and only 9 percent by capital intensity. 
Technology is even more pivotal in today's world economy. 
Thus, the amount of R&D expenditures and how these expendi-
as "applied research" while research with no immediate application is referred 
to as "pure research." As is the practice in the United States, the following 
generally do not fall under the definition of accounting for R&D costs: research 
under contract for others, physical plant for research activities, and costs in-
curred in the extractive industries. 
2
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tures are accounted have important economic impact on the 
future. 
In an unpublished study of 182 research intensive corpora-
tions, 62 percent of the respondents spent from 25 percent to 
350 percent of profits in R&D costs [Nix, 1972]. Unfortunately, 
the rate at which U.S. companies are increasing their R&D ef-
forts is declining: "[a] wave of corporate restructuring and a 
continuing emphasis on short-term profits are pushing R&D 
spending back into the doldrums of the mid-1970s" [R&D 
Scoreboard, 1988]. According to the National Science Founda-
tion, the first real decline in R&D expenditures in the past four-
teen years occurred in 1989 [Tax Foundation, 1990]. The Indus-
trial Research Institute's Annual R&D Trends Survey indicates 
that 1992 will see a slowdown in the growth of industrial R&D 
in the United States [November, 1991]. 
A major Japanese competitive trade advantage over the U.S. 
is Japan's heavy emphasis on the process-applied area of R&D 
while utilizing advanced technology from the West [Mansfield, 
1988]. Although this emphasis on process-applied R&D is not 
likely to change in the near future, Japanese firms now seem to 
devote about the same percentage of their R&D budget to risky 
long-term projects as American firms [Mansfield, 1988]. This 
differs significantly from the early 1970s when Japanese indus-
trial R&D was largely characterized by low-risk and short-term 
projects [Peck and Tamura, 1976]. Thus, the Japanese are in-
creasingly moving into long-term R&D as the means for creat-
ing future innovative products and securing a long-term trade 
advantage. U.S. firms may be reluctant to invest in long-term 
R&D because of the expense-as-incurred financial reporting 
rules. Yet "[corporations in the U.S.A. are beginning to realize 
the intellectual property may be their most valuable asset in 
competing with Japan" [Dreyfuss, 1987]. 
The theoretical foundation for the current requirement of 
expensing R&D costs as incurred certainly may be questioned. 
The accounting model with the annual measurement of income 
may be best suited for an agrarian economy characterized by 
manual labor and a static technology. However, income may 
not be as easily or exactly measured in an industrialized 
economy characterized by long-lived capital assets and a rapidly 
changing technology. A longer time perspective then the annual 
accounting measurement cycle may be required to measure per-
formance of many companies which sell technology based prod-
ucts. 
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In regard to the financial treatment of R&D costs, current 
practice may be defective in the following respects: (1) matching 
of revenue and associated costs often is not achieved, (2) R&D 
is a major asset but may not be presented as such, and (3) 
disclosure of R&D costs has not kept pace with its increasing 
importance. In short, methods used in accounting for R&D 
costs may not present a realistic picture of economic conse-
quences of the firm's research and operating activities. 
Accounting income is estimated by matching expenses and 
revenues over the appropriate time period with cost allocation 
being essential to the matching process. In a rapidly changing 
technology, however, the useful lives of capital assets become 
inordinately difficult to estimate. Technology may render a 
plant obsolete many years before it wears out. The lives of many 
assets are determined by technological change. Therefore, cost 
allocation to determine annual profits becomes even more diffi-
cult, yet more important, given a rapidly changing technology. 
If capital assets are currently expensed, this allocation distorts 
present income even more than capitalization [Thomas, 1969]. 
Imagine expensing a multimillion dollar plant during construc-
tion. Current accounting rules for R&D costs have the same 
effect because intangible assets arising from research costs are 
expensed in the year they are incurred. As Bierman and Dukes 
conclude, "[t]he result of expensing R&D may distort corporate 
decision making and lead to faulty measurement of income and 
changes in income through time. Business firms do not gener-
ally begin new product or process development projects until 
the principal technical uncertainties have been resolved" 
[Bierman and Dukes, 1975]. 
A study of 200 companies on the Fortune 500 list suggested 
that new ventures need, on average, eight years before they 
reach profitability [Biggadike, 1979]. Therefore, it may be that 
many R&D expenditures fit the FASB definition of an asset, like 
expenditures for capital equipment which are required to be 
capitalized. This is to say that R&D expenditures are made with 
the expectation of future benefits and are subject to reasonable 
measurement. Because R&D costs are incurred to secure future 
benefits, expenditures for R&D costs should be capitalized as 
assets and allocated to expense in the periods in which they 
help generate revenues. 
If one accepts the hypothesis that capital markets are effi-
cient in the procuring of information, "[d]isclosure of the 
4
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amount of research and development expenditures is an ex-
tremely important first step" [Bierman and Dukes, 1975]. As 
suggested by Drebin [1966], either cost-allocation procedures or 
current market values are preferable to expensing-as-incurred 
for reporting R&D costs. 
In support of capitalization of R&D costs and the matching 
principle, though the timing of benefits from R&D costs is un-
certain, an appropriate allocation arguably is better than an im-
mediate write-off. A subjective estimate of the value is better 
than an arbitrary write-off to no value [Drebin, 1966]. However, 
for such subjective estimates to be an improvement, a consider-
able amount of attention would have to be given in the develop-
ment of industry guidelines. An analysis into what type(s) of 
R&D should be capitalized and at what stage of completion 
R&D should be capitalized would be necessary. Such efforts 
could result in a much better matching of these costs and re-
lated revenue. Other researchers indicate that the current ex-
pense treatment for R&D costs may be in conflict with the 
matching principle of financial reporting [Bierman and Dukes, 
1975]. 
Historically, the accounting for R&D costs has ranged from 
requiring that all R&D costs be expensed in the year incurred 
(generally the current practice in the United States) to that of 
deferring and thereby allocating and matching R&D costs to the 
periods to which they help generate revenue. Although tax con-
siderations should not be allowed to dictate accounting theory, 
the income tax aspects of accounting for R&D have had an im-
pact on the choice of methods used to expense R&D costs. Prior 
to 1954, tax law required that the deduction of R&D costs con-
form to the timing of the reported expense in the financial state-
ments. Therefore, by immediately expensing R&D costs in the 
period incurred, the corporation received an immediate write-
off for tax purposes [Raby, 1964]. After 1954, corporations 
could get an immediate tax deduction for R&D expenditures 
whether expensed or capitalized for financial reporting pur-
poses. Despite the ability to get the deduction irrespective of 
accounting treatment, after 1954 most companies continued the 
practice of expensing R&D costs for accounting purposes. 
Although the choice of methods in financial reporting of 
R&D costs is no longer allowed, there seems to be little com-
plaint from management that R&D costs ought to be capitalized 
and amortized, rather than expensed. The apparent satisfaction 
of management with the current accounting rule of "expense-as-
5
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incurred" may be due to the fear that if financial accounting 
rules allow or require capitalization of R&D costs, the tax rules 
might be changed and the immediate write-off for tax purposes 
may be lost. The lack of groundswell support by management 
for changing the accounting for R&D costs may also be due to 
concerns over the problem that could be created if capitalized 
R&D costs suddenly must be written-off because the research 
proved unproductive, and, as a result, a large loss occurred. 
Managers also seem to be concerned that capitalizing R&D 
costs may complicate consolidated reporting, especially when 
entities with capitalized R&D costs are acquired or disposed. 
The satisfaction of corporate management with the expensing of 
R&D costs may also be due to the rule giving management the 
ability "to manage income" of a given accounting period by cut 
ting or accelerating R&D expenditures. Finally, the current 
practice of expensing R&D costs may be preferred by manage-
ment because managers feel that the company currently has the 
freedom to extensively disclose (or alternatively not to exten-
sively disclose) in the notes to the financial statements the infor-
mation that management wants to convey to the investor about 
R&D activities. 
Given this background about R&D, the problem with the 
current accounting treatment and the apparent lack of demand 
for change, the history of accounting for R&D costs is traced in 
the sections that follow. Exhibit I contains a historical overview 
of the major events in R&D accounting. These events are dis-
cussed in detail in the sections that follow. 
THE HISTORICAL RECORD (1917 TO PRESENT) 
A search of accounting literature reveals no reference to 
accounting for R&D costs prior to 1917. However, in 1917 the 
Federal Reserve Board [Federal Reserve Bulletin, 1917] accepted 
R&D as a deferred charge in published financial statements. 
The Federal Reserve Board reaffirmed this position in 1929 
[Federal Reserve Bulletin, 1929]. 
At approximately the same time other institutions, such as 
the National Association of Cost Accountants, promoted the 
same deferral treatment. In the 1924 edition of the National 
Association of Cost Accountant's Bulletin, the following state-
ment is found: 
It is perfectly proper to carry (the cost of developing a 
new article or line) as a deferred account, and an esti-
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Exhibit I 
A Historical Summary of the Financial 
Accounting fo r R & D in the United States 
1917 Federal Reserve Board — Deferral supported. 
1924 NACA — Deferral supported. 
1926 NACA — Deferral reaffirmed. 
1929 Federal Reserve Board — Deferral reaffirmed. 
1920-
1930s IRS — Deferral preferred. 
1954 AICPA — Deferral supported only if there is a reasonable connection 
to future operations. 
Prior 
to 1954 Tax law allowed expenditures to be expensed only when the same 
procedure was followed in the financial statements. 
1954 Tax legislation allows direct write-off regardless of the financial ac-
counting treatment. 
1960s Gellein — Disclosure varies considerably. 
1964 Raby — Majority of companies expense as incurred because of estab-
lished practice prior to 1954 tax legislation. 
1972 APB No. 22 and SEC No. 125 — Mandatory disclosure in the finan-
cial statements and annual 10K report. 
1975 SFAS No. 2 (1974) — Direct write-off mandated. Disclosure required. 
Expenditures defined. 
1985 SFAS No. 86 — Later capitalization and subsequent write-off al-
lowed on computer software expenditures with proven feasibility. 
1985 to 
Present Direct write-off required. Later capitalization and subsequent write-
off allowed on computer software expenditures with proven feasibil-
ity. Disclosure varies considerably. 
mate should be made to ascertain the number of units 
or volume of sale or units, as well as an estimate of the 
length of time over which this development will be 
spread [1924]. 
But, 
. . . experimenting (covering the current or minor ex-
perimenting that is continual in most manufacturing 
establishments) should be charged against current op-
erations each month as the money is expended and as-
sessed against the lines of products affected [1924]. 
In 1926, the National Association of Cost Accountants again 
stated that it was acceptable to capitalize the cost of developing 
a new product (to defer R&D expenses) " . . . if you are starting 
out with a new product in which you have a very definite knowl-
7
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edge that there is a field for it, and you are going to spend a lot 
of money, and you know it is going to come back to you" 
[1926]. At its 1954 annual meeting, the American Institute of 
Certified Public Accountants supported the deferral treatment 
only if future benefits were definite: "Development expenses 
should be deferred only in those cases where they have a rea-
sonable connection with future operations" [Higgins, 1954]. 
Thus, accounting organizations had generally supported the de-
ferral treatment for research and development expenditures. It 
may be seen, however, that the definition of what could be de-
ferred became, over time, more conservative and restrictive. 
Paton [1955] supported the deferral treatment in an accounting 
text: 
On the other hand, whenever research and related costs 
are incurred in substantial amount on a particular 
project which is expected to result in a valuable new 
process, perhaps patentable, there is much to be said 
for deferring followed by systematic absorption in later 
years. 
Perhaps the most influential institution affecting the ac-
counting treatment of research and development costs has been 
the Internal Revenue Service. The Internal Revenue Service tax 
policy in the 1920s and 1930s favored the deferral treatment of 
research and development costs. From the beginning, early tax 
court decisions and accounting literature supported research 
and development cost deferral; but scientists and economists 
supported immediate deduction for tax purposes as a means to 
stimulate research and development. 
Businessmen, constantly on the alert for immediate ben-
efits, increased political pressure on Congress to allow the im-
mediate deduction of R&D costs for tax purposes. However, the 
tax law prior to 1954 allowed the current expensing of research 
and development only when the same procedure was followed 
in the financial statement. Thus, before 1954, business firms 
may have switched from deferral to current expensing of re-
search and development in published financial statements to 
take advantage of the tax benefits of immediate deduction. 
In 1954, Congress passed tax legislation which allowed for 
the immediate deduction of R&D costs as they were incurred; 
these deductions could be taken irrespective of the financial ac-
counting treatment of these costs. Thus there was no longer a 
tax requirement that R&D costs be treated for tax purposes ac-
8
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cording to the treatment on the financial statements. Interest-
ingly, in 1954 Congress merely removed the tax-financial ac-
counting conformity requirement. Congress still permitted the 
taxpayer to elect to capitalize and amortize R&D costs for tax 
purposes or to deduct these costs as incurred. This tax election 
for R&D costs continues today. 
The following quotation from the Senate Finance Committee 
Report on the Internal Revenue Code of 1954 illustrates the in-
tent of Congress in making the tax law change: 
No specific treatment is authorized by present law for 
research and experimental expenditures. To the extent 
that they are ordinary and necessary they are deduct-
ible; to the extent that they are capital in nature they 
are to be capitalized and amortized over useful life. 
Losses are permitted where amounts have been capital-
ized in connection with abandoned projects, and recov-
ery through amortization is provided where useful life 
of these capital items is determinable, as in the case of 
a patent. However, where projects are not abandoned 
and where a useful life cannot definitely be determined, 
taxpayers have had no means of amortizing research 
expenditures. 
To eliminate uncertainly and to encourage taxpayers to 
carry on research and experimentation the House and 
your Committee's bill provide that these expenditures, 
incurred subsequent to December 31, 1953, may, at the 
option of the taxpayer, be treated as deductible ex-
penses. It also provides that a taxpayer may elect to 
capitalize such expenditures and if no other means of 
amortization is provided, may write them off over a 
period of not less than 60 months, beginning with the 
month in which benefits are first realized. [Higgins, 
1954]. 
Raby logically asserts that the majority of companies were 
probably currently expensing research and development in the 
mid-sixties because of income tax law prior to 1954. "Perhaps a 
major force underlying this accounting treatment is that before 
1954 what was done in the books and financial statements con-
trolled what was allowed to be done on tax returns" [Raby, Au-
gust 1964]. Furthermore, once this practice was established, it 
was continued regardless of the post-1954 tax impact. Raby [Au-
gust 1964] states, "[a]s a consequence, companies quite logically 
set up [the] practice of expensing research expenditures, and 
9
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this practice has continued since, even though tax justification 
for doing so has ceased to exist." 
Indeed, a survey of 244 companies in the 1960s [Gellein and 
Newman, 1973] disclosed that the common practice was to cur-
rently expense research and development expenditures. The in-
vestigation also revealed 60 percent of the companies disclosed 
the dollar amount of research and development in some way, 
but only 10 percent disclosed the accounting treatment in pub-
lished financial statements. Therefore, comparability of finan-
cial statements was difficult. 
Acceptance of the current expense treatment for research 
and development expenditures in accounting practice is re-
vealed in the accounting literature. Braithwaite [1967] said in 
an article in Accountancy, "The [British] auditor . . . will take a 
jaundiced attitude to any attempt to capitalize research expendi-
tures on the grounds of expected future benefits to the com-
pany." Thus, auditors were most comfortable when research 
and development costs were expensed; but Braithwaite stated 
further, "[t]he auditor . . . may agree that in the long run a 
research program necessarily must be judged by its overall fruit-
fulness." The contradiction in Braithwaite's statements about 
current expensing of research and development and future ben-
efits from research and development is obvious. 
Auditors have an incentive to support the immediate write-
off of research and development expenditures to avoid unneces-
sary audit risk. Prior to the SFAS No. 2 [1974] expense require-
ment, business firms had (and still have) an incentive to capital-
ize research costs having little future benefit so current earnings 
would be more impressive. When it became apparent to the 
auditor and to others that these costs had no future benefit, 
they were written off. If the write-off caused sharp reduction in 
profits and investors saw their investments decline in value, the 
auditor might face investor liability suits for being a party to 
misleading prior financial statements. Thus, much of the sup-
port for expensing R&D costs as incurred came from auditors 
who otherwise might face difficulty in evaluating R&D costs. 
Prior to SFAS No. 2 [1974], four basic questions regarding 
the official accounting treatment of R&D in financial statements 
remained unanswered: (1) What activities should be included in 
R&D? (2) What portion, if any, of the costs related to these R&D 
activities should be deferred? (3) How should these deferred 
costs be amortized? (4) How should R&D be disclosed in the 
10
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financial statements? These unanswered questions made the 
comparability of R&D information between companies and, for 
a company, between years very difficult. Also, these questions 
made current and future financial accounting for R&D very dif-
ficult. 
Prior to SFAS No. 2, R&D expenditures were sometimes 
classified as separate expenses on the income statement. Some 
companies included R&D expenses with other expenses, yet 
other companies included R&D in the cost of goods sold. Also, 
management had the flexibility of either currently expensing 
R&D or capitalizing R&D and writing it off over future time 
periods. Large write-offs of capitalized R&D costs would occur 
unexpectedly when it became apparent that the expenditures no 
longer had a future benefit. The variety of accounting treat-
ments of R&D costs led to criticism over the lack of uniform 
accounting. 
Because of criticism over the variety of methods of account-
ing for R&D, action was taken by the Accounting Principles 
Board (APB) and the Securities and Exchange Commission 
(SEC) in 1972. The APB Opinion No. 22 [1972] made the disclo-
sure of R&D expenditures in financial statements mandatory. 
Also, the SEC required the reporting of R&D in the Annual 10-K 
Report. Although badly needed, the disclosure requirements of 
the APB and the SEC did not solve the problem of the "proper" 
accounting treatment for R&D costs in financial reporting. 
However, these disclosures made apparent to financial state-
ment users the significance of R&D expenditures in relationship 
to accounting measurements. 
A BRIEF SUMMARY AND CRITIQUE OF SFAS NO. 2, 
ACCOUNTING FOR RESEARCH AND DEVELOPMENT COSTS 
As of January 1975, the Financial Accounting Standards 
Board (FASB) required the expensing of all R&D expenditures 
during the year incurred. The two exceptions to this rule are (1) 
R&D under contract for others, and (2) plant and equipment 
(an R&D lab) which has alternative future uses. A further excep-
tion was made by the SFAS No. 86 [1985] for the capitalization 
of computer software for which technological feasibility has 
been established. 
In SFAS No. 2, FASB recognized the problems associated 
with the accounting for R&D costs. However, the FASB did an 
inadequate amount of research on the problem before making 
11
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its decision in 1974: "[t]he FASB did not undertake a major 
research effort for the project. The FASB staff interviewed a 
limited number of selected financial analysts and commercial 
bankers and reviewed a substantial number of published finan-
cial statements" [SFAS No. 2, Para. 20, 1974]. Consequently, the 
effect of the current expense treatment on the total dollar 
amount of R&D was not carefully considered. Thus, the now 
established practice of currently expensing R&D costs may not 
be appropriate for all investments or business firms. The cur-
rent expense-as-incurred practice may well have reduced R&D 
costs in total and caused a shift from "pure" to "applied" R&D. 
The need to maintain current reported profits and earnings per 
share may have resulted in a change in type and amount of 
R&D expenditures. 
The major objectives of the Statement were (1) to provide 
more uniformity in accounting reporting for R&D; and (2) to 
provide useful financial information about R&D. FASB State-
ment No. 2 defines R&D activities, identifies costs associated 
with these activities, and specifies the accounting treatment and 
disclosure of these costs. It specifically excludes certain activi-
ties found only in the extractive industries, but includes R&D in 
other industries. 
In Statement No. 2, FASB discussed four alternatives in 
accounting for R&D. These four alternatives are: 
1. Charge all costs to expense when incurred; 
2. Capitalize all costs when incurred; 
3. Capitalize costs when incurred if specified condi-
tions are fulfilled and charge all other costs to ex-
pense; 
4. Accumulate all costs in a special category until the 
existence of future benefits can be determined [SFAS 
No. 2, 1974]. 
Accounting theory supports alternative three, which is to: 
. . . capitalize costs when incurred if specified condi-
tions are fulfilled and charge all other costs to expense" 
[SFAS No. 2, 1974]. Consequently, when research and 
development expenditures are expected to benefit fu-
ture time periods, they should be capitalized and amor-
tized over the periods benefited. This capitalization and 
future write-off is consistent with the matching concept 
as defined by the Financial Accounting Standards 
Board. The pronouncement refers to matching as, 
"identifying, measuring, and relating revenues and ex-
12
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penses of an enterprise for an accounting period" 
[FASB, 1974]. 
However, the FASB still chose the first alternative which is, 
. . charge all costs to expense when incurred" [1974]. As sup-
port for this decision, the FASB utilized research studies that 
emphasized a high failure rate for R&D. For example, 
one study of a number of industries found that an average of 
less than 2 percent of new product development projects were 
commercially successful" [Higgins, 1954]. Another study esti-
mated exceedingly high new product failure rates, ranging from 
30 to 90 percent. In all likelihood, these studies were not and 
are not representative of typical research and development 
projects. Other studies indicated more optimistic results. 
Mansfield [May, 1972] found more than 75 percent of the 
projects he examined had estimated probabilities of success of 
80 percent or greater. Forty-four percent of these projects were 
technically successful, and only 16 percent were technically un-
successful. Scherer [1970] attributes this high success ratio to 
the fact that ". . . business firms do not, as a rule, begin new 
product or process development until the principle technical 
difficulties have been whittled down through inexpensive re-
search, conducted either by their own personnel or by outsid-
ers." Thus, R&D success is much higher than inferred in the 
Board's decision. 
The FASB [1974] also states, " . . . a direct relationship be-
tween R&D and specific future revenue generally has not been 
demonstrated." However, as previously stated, many projects 
are successful and future revenue is directly related to them. 
Numerous studies [Minasian, May 1969] have been undertaken 
to show this relationship; they have had some success in linking 
R&D activity with future revenue amounts, even though the 
studies encountered data problems. Most of these studies use 
the number of patents or number of employees as statistical 
data, rather than the dollar value spent on R&D. Additional 
study of the outcomes of research, with actual R&D expenditure 
data, may prove enlightening to accounting rule makers. 
The FASB [1974] indicated, ". . . at the time most R&D 
costs are incurred, the future benefits are, at the most, uncer-
tain." This statement implies there is no economic resource cre-
ation. If no future benefits are generated, it would certainly be 
irrational for a firm to undertake an R&D project. However, 
many studies show the marginal rate of return on R&D is either 
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comparable to or greater than investment return on the capital 
expenditures. Denison [1962] calculated the rate of return on 
R&D to be about the same as for plant and equipment expendi-
tures, but he assumed no time lag. The return rate for R&D 
investment would have been much greater with a time lag. 
Grilich [1964] found the rate of return for investment in agricul-
tural research to be between 35 and 170 percent. More specifi-
cally, Mansfield [May 1972] estimates the marginal rate of re-
turn on R&D in the petroleum industry to be over 40 percent, 
while in the chemical industry, Minasian [May 1969] estimates 
a 50 percent marginal rate of return on R&D. 
Referring to the total economy, Fellner [1970] estimates the 
rate of return on R&D to be in excess of 18 percent. Assuming a 
static technology, 18 percent is much greater than the marginal 
rate of return from plant and equipment. Consequently, con-
trary to the FASB opinion, there was tangible evidence of re-
source generation at the time of the R&D expenditure. Perhaps 
a final irony can be found in the following statement from the 
FASB. R&D should not be capitalized even when future benefits 
are known simply because they " . . . cannot be measured with a 
reasonable degree of accuracy . . ." [SFAS No. 2, 1974]. Follow-
ing this reasoning, fixed assets, such as plant and equipment, 
would not be capitalized because the future productivity of 
fixed assets is subject to uncertain marketing conditions and 
rapid technology change. Who can estimate accurately the busi-
ness life of fixed assets? For example, nuclear power plants may 
be closed on a moment's notice. Under the same rationale, 
"goodwill" in a purchase of a business would never be shown 
on the balance sheet and the intangible drilling cost of a "wild-
cat" oil well, whether "wet" or "dry" can never be an asset. Thus, 
in comparison to other costs that are capitalized, R&D costs do 
not seem to be of any greater uncertainty or risk. 
Given the reasoning behind the FASB's decision, it may be 
concluded that SFAS No. 2 had, at best, a questionable theoreti-
cal foundation in support for its treatment of R&D costs. 
THE HISTORICAL RECORD FOLLOWING THE 
1974 ENACTMENT OF SFAS NO. 2 
A considerable amount of financial accounting research 
was conducted subsequent to the 1974 issuance of SFAS No. 2 
to determine the impact, if any, of the expense-as-incurred re-
quirement on R&D expenditures. A central thrust of this re-
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search concerned whether the expense-as-incurred rule might 
result in decreased corporate spending on R&D in order to 
maintain profit levels. 
The contradictory findings of much of this research were 
published in a special supplement to the 1980 Journal of Ac-
counting Research. Horwitz and Kolodny [1980] concluded that 
the rule did, in some cases, reduce R&D expenditure. "We con-
clude that the evidence supports the premise that the expense 
only rule caused a relative decline in R&D outlays for small high 
technology firms which had primarily used the deferred method 
of measurement." 
Other researchers such as Dukes, Dyckman and Elliott 
[1980] concluded that SFAS No. 2 did not have any effect on 
R&D expenditures: "all three sets of tests fail to support an ef-
fect on research and development expenditures attributable to 
SFAS No. 2." Wolfson [1980] notes that Horwitz and Kolodny 
provided " . . . no evidence of market inefficiencies occurring as 
a result of SFAS No. 2." Vigeland [1981] reports that ". . . no 
market reaction was observed." In other words, lacking evidence 
to the contrary, we must conclude investors are aware of the 
impact of SFAS No. 2 on reported earnings. This suggests that 
the price of a company's stock would not decrease in response 
to the effect of SFAS No. 2 on reported earnings, and the com-
pany would not be motivated to reduce R&D expenditures as a 
result of the rule. 
Most researchers would probably agree that we do not un-
derstand the R&D decision making process. Authors such as 
Ball [1980] state there is an almost complete absence of theory 
on the determination of R&D expenditure and accounting 
policy choice. Marshall [1980] states, "[t]he process of determin-
ing R&D expenditures, including the choice and role of account-
ing method is so complex that designs such as those used by 
Dukes, et. al., and Horwitz and Kolodny are incapable of pro-
ducing creditable results." If nothing else, the research of the 
late 1970s has forced us to acknowledge we may draw no firm 
conclusions in regard to the impact of SFAS No. 2 on R&D 
expenditures. 
Although additional research was conducted in the 1980s 
regarding the impact of SFAS No. 2, few, if any, conclusive find-
ings were made. In 1984, Elliott, Richardson, Dyckman and 
Dukes attempted to reconcile the results of the 1980 Horwitz 
and Kolodny study with their study [1980] which did not show a 
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SFAS No. 2 effect. The results of the 1984 study were again 
inconclusive. Interestingly, this study did show a relative decline 
in R&D expenditures prior to the 1974 issuance of SFAS No. 2. 
Elliott, Richardson, Dyckman and Duke [1984] suggest that we 
cannot conclude that SFAS No. 2 caused changes in R&D ex-
penditures. In a 1984 investigation of managers' adoptions to 
SFAS No. 2, Selto and Clouse also found inconclusive results in 
regard to the effect of the FASB mandated expensing of R&D 
requirement. However, Daley and Vigeland [1983] observed that 
" . . . R&D capitalizing firms were more highly levered, employed 
more public debt, and had a higher ratio of dividends to unre-
stricted retained earnings, and were smaller in size than R&D 
expensing firms." This finding hints that the FASB requirement 
had an economic impact on these smaller R&D firms. 
A 1987 study of R&D management and corporate financial 
policy by Guerard, Bean and Andrews analyzed the relationship 
of R&D investment, dividends and new debt financing deci-
sions. Not surprisingly, they found significant relationships 
among these variables. They concluded that changes in these 
variables occurred simultaneously and could not be considered 
independently. In regard to the effect of SFAS No. 2, the effi-
cient market hypothesis that stock prices reported the impact of 
R&D expenditures whether they were capitalized or not was 
neither confirmed nor denied. 
Horwitz and Normolle examined the effect that SFAS No. 2 
had on small technology firms in securing R&D awards from 
federal agencies [1989]. The study explored whether the detri-
mental effect of the expense-as-incurred requirement on small 
firms' financial ratios might make the firms ineligible for gov-
ernmental R&D contracts. As a result of SFAS No. 2, the finan-
cial ratios of these companies were negatively affected, but no 
evidence was found that the expensing requirement reduced the 
amount of R&D awards by federal agencies to small research 
intensive companies. 
DISCLOSURE OF RESEARCH AND DEVELOPMENT 
EXPENDITURES CURRENT PRACTICE 
Disclosure of R&D expenditures is, today, not unlike that 
existing prior to 1975 when SFAS No. 2 was implemented. Cor-
porations, in their annual reports, display a wide variety of in-
formation regarding R&D expenditures. Some companies pro-
vide no disclosure, others offer considerable detail. The annual 
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dollar amount of R&D by year is often separately disclosed on 
comparative income statements. Occasionally, either in the 
notes or in management's discussion of corporate activities, in-
formation is provided for R&D such as percentage of operating 
revenue, percentage change from the previous year, number of 
full-time R&D employees, and directions the R&D effort is tak-
ing. It appears that management of these companies disclose 
what they want with regard to the firm's R&D activities. 
Although companies are required to expense R&D costs in 
the year incurred, there is still considerable latitude in what 
management discloses to investors. It seems that companies in 
which R&D activities reflect favorably upon them take ample 
opportunity to disclose such; other companies for various rea-
sons provide little or no information regarding their R&D ef-
forts. Thus, irrespective of the required current expensing of 
R&D, stockholders are frequently not well informed about R&D 
efforts. 
A BRIEF SUMMARY AND CRITIQUE OF SFAS NO. 86 
ACCOUNTING FOR THE COSTS OF COMPUTER SOFTWARE 
TO BE SOLD, LEASED OR OTHERWISE MARKETED 
The costs of developing computer software that is to be 
marketed are similar to R&D costs. In both cases, the costs are 
mainly salaries of personnel who are engaged in the projects. 
Software development costs and R&D costs are also somewhat 
similar as to uncertainty of outcomes, (risks and revenue 
amounts) and as to long periods of time between expenditures 
and sales. Given these similarities, it is interesting to note the 
contrast in accounting for the costs related to developing com-
puter software of software vendors to costs of R&D of a drug 
manufacturer, biotechnology firm or even to the R&D costs of a 
computer hardware manufacturer. 
Before the issuance of SFAS No. 86 in 1985, the financial 
statements of computer software companies provided inad-
equate disclosure about software development costs, and com-
parisons between companies in the industry were hampered by 
the variety of accounting practices for software development 
costs. Thus, the latter problem was very similar to the R&D cost 
situation prior to SFAS No. 2, while the former problem is still 
unresolved with regard to R&D today. 
SFAS No. 86 [1985] addressed the issue of whether software 
producers should expense development costs as they are in-
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curred or capitalize them on the theory that the cost is creating 
a productive asset. The potential impact of this issue is reflected 
in the fact that the computer software industry spent $7 billion 
in 1985 [Chakravarty and Kolseka]. SFAS No. 86 requires soft-
ware producers to expense development costs while the product 
is still in the R&D phase; but as soon as the product is "techno-
logically feasible," companies must capitalize any further devel-
opment costs and amortize them over the life of the product, 
The practical problem in applying this statement is determining 
at what point in time a product becomes technologically fea-
sible. This is particularly a complex problem in the case of com-
puter software which is often redesigned. 
SFAS No. 86's treatment of software development costs fol-
lows the conceptual definition of an asset in financial account-
ing: an asset is a cost which benefits a future accounting period. 
However, the Statement did not resolve the problem of the lack 
of inter-company comparability of financial statements. For in-
stance, in 1984 IBM capitalized 67 percent of its investment in 
software products while other companies reported capitalizing 
between 3 to 25 percent of their software development costs 
[Chakravarty and Koselka]. Thus it appears that SFAS No. 86 
may not accomplish its intended purposes of providing better 
disclosure and making software companies' financial statements 
more comparable. The practical effect of the statement was to 
allow software companies to determine when a product's asset 
life begins. The software firm must make this critical account-
ing decision to determine what costs to capitalize for each soft-
ware development project. As a result, there is still difficulty in 
comparing companies within the industry from their financial 
statements. 
The experience with capitalization of software development 
costs is instructive if changes to the accounting for R&D costs 
are ever considered. Even though being more conceptually cor-
rect, the capitalization of R&D costs will not automatically pro-
duce pragmatic improvement. Indeed, less comparability be-
tween companies financial statements could result. If capitaliza-
tion of R&D costs became the financial accounting rule, there 
would probably be a requirement that a project reach "techno-
logical feasibility" before costs could be capitalized. Again, like 
the experience with software development costs, such a vague 
rule causes a wide range of interpretations and could cause the 
problem of lack of comparability of financial statements be-
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tween R&D firms as well. Thus it is important, if changes to the 
accounting for R&D are made to allow capitalization of costs, 
that classification criteria be set forth as well to specify pre-
cisely when capitalization would begin in an R&D project. 
THE HISTORICAL RECORD OF FINANCIAL ACCOUNTING 
FOR R&D COSTS IN OTHER SELECTED COUNTRIES 
In other English-speaking nations, i.e., Australia, Canada, 
Great Britain, Ireland, etc., the capitalization of at least some 
R&D costs is permitted. This practice usually has caused a 
myriad of problems in defining research development and vari-
ous types of research such as pure research versus applied. As 
with the "technologically feasible" U.S. requirement for software 
development costs, these distinctions are important to deter-
mine which costs are capitalized from those that are expensed. 
As with the U.S. software costs, interpreting the rules and apply-
ing the distinctions can vary from company to company. Thus, 
accounting for R&D costs, even within one country, can vary 
considerably. As will be examined in this section, there is great 
variation and problems with the accounting treatment around 
the globe. 
In 1983, the Australian accounting profession issued the 
standard "Accounting for Research and Development Costs" 
(AAS No. 13). The objectives of the standard were similar to 
those of SFAS No. 2 issued in 1974: to provide useful informa-
tion regarding R&D costs and to reduce the number of alterna-
tive accounting practices for R&D expenditures [Carnegie and 
Turner, 1983]. 
Attempts were made in AAS No. 13 to distinguish between 
research and development costs and between basic and applied 
research. The definitions, not surprisingly, were difficult to 
work with as observed in the following passage taken from AAS 
No. 13: 
4(a) Research means planned investigation undertaken 
with the hope of gaining new scientific or technical 
knowledge and understanding which will be useful in 
developing a new product or service (hereinafter prod-
uct), or a new process or technique (hereinafter pro-
cess), or in bringing about a significant improvement to 
an existing product or process. 
4(b) Development means the translation of research 
findings or other knowledge into a plan or design for a 
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new product or process or for a significant improve-
ment to an existing product or process. 
AAS No. 13 further divided research into basic research and 
applied research. Basic research was defined as ". . . original 
investigation directed primarily towards the advancement of 
knowledge," while applied research was defined as . . original 
investigation directed primarily towards solving recognized 
practical problems." This distinction was made to assist the 
practitioner in evaluating the classification of specific costs. 
From these definitions, it appears distinguishing between devel-
opment costs and applied research costs is an enigmatic chore. 
AAS No. 13 allows "selective capitalization" in accounting 
for R&D costs; that is, some R&D costs may be capitalized or 
expensed in the period incurred while others must be currently 
expensed. In general, both applied research and development 
costs could be capitalized. Basic or pure research is required to 
be expensed in the period incurred. Although the theory behind 
AAS No. 13 is sound, the practical difficulties in defining and 
distinguishing between research costs (pure and applied) and 
development costs limit the usefulness of the approach. 
In Canada, there is a very basic difference between Cana-
dian and United States' accounting rules for R&D costs; in 
Canada development costs should be deferred to future periods 
if all of the following criteria are satisfied: 
(a) the product or process is clearly defined and the 
costs attributable thereto can be identified; 
(b) the technical feasibility of the product or process 
has been established; 
(c) the management of the enterprise has indicated its 
intention to produce and market, or use, the prod-
uct or process; 
(d) the future market for the product or process is 
clearly defined or, if it is to be used internally 
rather than sold, its usefulness to the enterprise has 
been established; and 
(e) adequate resources exist, or are expected to be 
available, to complete the project. (CICA Handbook, 
Aug. 1978). 
By contrast, development costs in the United States must be 
expensed in the period incurred. 
In Great Britain, the accounting profession has taken the 
position that both pure and applied research should be ex-
pensed in the period incurred [SSAP No. 13 revised, Jan. 1989]. 
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However, the British Accounting rules distinguish the develop-
ment of new products and services from pure and applied re-
search; these development costs, under certain circumstances, 
should be deferred. It is the authors' opinion these distinctions 
(which possess the same difficulties as those used in Australia) 
are very difficult to define and utilize. 
The reasoning behind the British requirements of expensing 
pure and applied research is that these costs are regarded as 
part of continuing operations required to maintain a company's 
competitive position. Therefore, these costs cannot be placed on 
the balance sheet as assets, but should be expensed in the pe-
riod incurred. Also required is a significant amount of disclo-
sure about the R&D activities of the period. If development 
costs meet the rigid criteria specified in SSAP No. 13, they are 
defined as intangible assets for balance sheet purposes and are 
amortized as expense in revenue generation or written off im-
mediately if found to be worthless. 
The International Accounting Standards Committee takes 
the position that research and development costs should usually 
be charged to expense in the period in which they are incurred 
[1980]. However, notes the Committee, ". . . if it can be demon-
strated that the product or process is technically and commer-
cially feasible and that the enterprise has adequate resources to 
enable the product or process to be marketed—it may be appro-
priate to defer the costs of development activities to future peri-
ods." 
It can be seen that the United States and other nations 
share the difficulty of accounting for R&D costs. Despite prob-
lems of implementation and lack of comparability of financial 
statements in some cases, other nations are more sophisticated 
in distinguishing between types and stages of R&D. These coun-
tries specify accounting treatment according to the type of R&D 
costs. Perhaps, U.S. accounting should consider adopting some 
of the approaches used in these countries. 
SUMMARY 
Since research and development expenditures are signifi-
cant in amount, the historical accounting treatment of this im-
portant cost was investigated. Historical research reveals that 
accounting organizations, the Internal Revenue Service, and ac-
counting practice originally supported capitalization and future 
amortization of R&D expenditures. However, economic and so-
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cial forces exerted pressure for immediate write-off of R&D 
costs because of the income tax advantage. 
The Internal Revenue Service yielded to these forces but 
required that R&D costs be currently expensed in published fi-
nancial statements when immediate write-off for tax purposes 
was to be allowed. This tax requirement was reversed in 1954, 
but the current expensing technique had already become insti-
tutionalized into financial accounting. 
Auditors who examined published financial statements sup-
ported the established practice of currently expensing research 
and development costs. The difficulty in measuring future ben-
efits of the expenditures and the lack of tangible, physical evi-
dence were the main reasons given for this support. Also, man-
agement was reluctant to adopt accounting treatment that could 
result in an unexpected immediate write-off of R&D "assets" 
when deemed to have no future value. 
In 1974, the FASB issued Statement No. 2 which required 
that private research and development expenditures be cur-
rently expensed. The troublesome problem of whether to capi-
talize or to expense R&D costs was temporarily solved. No more 
would the write-offs of past capitalized R&D costs cause drastic 
declines in current income and in the stock price. 
SFAS No. 2 was pragmatically designed to temporarily 
handle the current problem of a lack of uniformity between 
companies in accounting for R&D costs. Uniformity in the ac-
counting for R&D costs was established by simply requiring all 
firms to expense R&D in the year incurred. Thus, unlike the 
treatment of other types of costs, R&D costs are arbitrarily ex-
pensed despite the fact that R&D meets the classic definition of 
an asset for the "future benefit" inherent in such expenditures. 
Also, apparently little analysis was undertaken by the FASB ei-
ther to consider the success rate of R&D expenditures or to 
consider the effect established practice would have on the dollar 
amount and on the type of private research and development in 
the United States. Nor was a close analysis undertaken by the 
Board to determine to what extent research and development 
might become a function of current profits as a result of the 
current expense treatment. In accounting research conducted 
since the issuance of SFAS No. 2 the impact of the requirement 
to immediately expense R&D costs on the amount of R&D ex-
penditures has been inconclusive. However, pressure is building 
for more adequate disclosure of R&D costs and toward some 
change in U.S. accounting rules to allow the capitalization of 
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some costs as permitted in numerous foreign nations and, 
within the U.S., as permitted for software development costs. 
CONCLUSIONS AND IMPLICATIONS 
FOR FURTHER RESEARCH 
In more and more industries, research and development is 
becoming the dominant asset. The accounting rules have not 
kept pace with adequately disclosing and capitalizing this cost. 
It is in both the investor's interest (in terms of rational decision 
making) and the accounting profession's (in terms of responsi-
bility to society and reputation) to reconsider the accounting for 
R&D costs on the financial statements and the amount of detail 
disclosed in notes to the statements. 
Corporate reporting of R&D can be improved in two ways: 
by disclosing more information about R&D spending and activi-
ties and by recognizing probable successful development expen-
ditures as an asset that will give future benefits. The difficulties 
encountered in determining at what point in time R&D costs 
become an asset must be adequately addressed. This has not yet 
been done. By contrast, in spite of the difficulties encountered 
with SFAS No. 86, accounting rules do allow software develop-
ment costs to be capitalized at some point in the development. 
Arguably, accounting should afford R&D costs similar treat-
ment. 
In contrast to the United States, a number of foreign na-
tions allow the deferment of at least some R&D costs, although 
many definitional problems of research, pure research, applied 
research, and development costs are encountered. 
More research is needed in the classification of R&D costs. 
Fortunately, a current study by the AICPA's Accounting Stan-
dards Executive Committee concerning the classification, capi-
talization and amortization of advertising costs clearly has im-
plications for the accounting treatment of R&D costs [Flesher, 
1979; also, Thompson, Hoskins, and Flesher, 1991]. This is es-
pecially true because advertising costs may be even more diffi-
cult to match with future revenue. Both R&D and advertising 
costs are "intangible" in nature, are material in amount and 
benefit future time periods. The expensing of either of these 
costs in the period incurred frequently violates the matching 
principle of accounting and distorts reported net income. 
Flesher explores the " . . . possibility of integrating qualitative 
marketing department information with that of accounting." 
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Similar research which integrates qualitative R&D department 
information with that of accounting may be appropriate. Also, a 
comprehensive study of foreign countries' economic treatment 
of R&D costs may be useful. 
One financial accounting alternative for R&D costs cur-
rently being investigated is to classify R&D costs as a contra 
stockholders' equity account when incurred rather than expens-
ing in the period incurred. This approach would eliminate the 
problem of calling R&D costs an asset and also would eliminate 
the negative effect on current net income presently experienced 
from expensing R&D costs when incurred. Another approach to 
be considered would be the capitalization of R&D costs in an 
account similar to organization costs and written off over a defi-
nite future time period regardless of revenue generation and 
recognition. 
Alternatively, accounting rule makers also should consider 
expensing general research costs and capitalization of those 
costs related to specific projects. These capitalized costs could 
be then matched with the future revenue of the project, unless 
the project's revenues prove too small to recover these capital-
ized costs which would lead to the write-off of the remaining 
capitalized costs of the project [Milburn, 1968]. Milburn defines 
general research as ". . . research of indirect benefit to the fu-
ture and its contribution cannot be related to specific future 
periods on a reasonable basis . . . and . . . specific development, 
if successful, as identifiable with specific future benefits." 
Milburn cites as support for his view APB No. 11, paragraph 
14d, Accounting for Income Taxes, which follows: 
Costs identifiable with future revenue or otherwise 
identifiable with future time periods should be deferred 
to those future periods. When a cost cannot be related 
to future revenues or to future periods on some basis 
other than revenues, or it cannot reasonably be ex-
pected to be recovered from future revenues, it be-
comes, by necessity, a cost or an expense of the current 
period (or in some cases of a prior period). 
The impact of SFAS No. 86, (accounting for the costs of 
computer software) on R&D expenditures in total amount and 
type offers a fruitful area for future research. Difficulties en-
countered in implementing the standard and how companies 
and investors have reacted to it should prove interesting. Also, 
the appropriateness of the selective capitalization of R&D in 
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specific industries, such as the drug industry, merits investiga-
tion. Furthermore, the impact of SFAS No. 2 on small develop-
ing companies should be researched in depth. Although this ar-
ticle has dealt primarily with the financial reporting of R&D 
expenditures, the tax aspects of this subject merit further re-
search. For instance, to what extent is the United States per-
forming R&D overseas due to the tax advantages of foreign 
countries? 
Accounting research into the feasibility and appropriate-
ness of capitalization and amortization of advertising costs 
clearly has implications for the financial accounting treatment 
of R&D costs, especially since advertising costs are perhaps 
more difficult to match with future revenue than are R&D costs. 
The direct costing approach in which only variable R&D costs 
would be capitalized and expensed over future time periods de-
serves further consideration. Given the historical controversy 
regarding the financial accounting of R&D costs, accounting 
researchers and policy makers should focus carefully on the im-
pact of the current accounting rules and analyze alternative ac-
counting treatments. 
In conclusion, the current requirement [SFAS No. 2] of ex-
pensing R&D costs as incurred for financial statement purposes 
is inappropriate. R&D costs are material in amount, benefit fu-
ture time periods, and should more clearly be matched with 
(charged to) the revenues they help generate. They also clearly 
fit the FASB definition of an asset. It is likely that corporations' 
fear of losing the R&D tax shelter and the loss of flexibility in 
managing reported profits via the timing of R&D expenditures 
are major obstacles to change in existing financial reporting 
requirements. However, a change in the financial reporting of 
these expenditures is in order. 
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